{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:23:45Z","timestamp":1789658625674,"version":"4.0.1"},"reference-count":2,"publisher":"Hindawi Limited","issue":"1","license":[{"start":{"date-parts":[[2012,9,14]],"date-time":"2012-09-14T00:00:00Z","timestamp":1347580800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2012,9,14]],"date-time":"2012-09-14T00:00:00Z","timestamp":1347580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1111\/jcpt.12006","type":"journal-article","created":{"date-parts":[[2012,9,15]],"date-time":"2012-09-15T02:59:55Z","timestamp":1347677995000},"page":"1-2","source":"Crossref","is-referenced-by-count":14,"title":["Do we need authorized orphan drugs when compounded medications are available?"],"prefix":"10.1155","volume":"38","author":[{"given":"M.","family":"Dooms","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Pinc\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Simoens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2012,9,14]]},"reference":[{"key":"10.1111\/jcpt.12006-BIB1|cit1","unstructured":"European Commission Regulation (EC) No 141\/2000 of the European Parliament and the Council of 16 December 1999 on orphan medicinal products"},{"key":"10.1111\/jcpt.12006-BIB2|cit2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2165\/11601640-000000000-00000","article-title":"Are some orphan drugs for rare diseases too expensive? A study of purchase versus compounding costs","volume":"27","author":"Simoens","year":"2011","journal-title":"Drugs Ther Perspect"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12006","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12006","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12006\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:04:38Z","timestamp":1671818678000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12006"}},"subtitle":["Unnecessary authorization of some orphan drugs"],"short-title":[],"issued":{"date-parts":[[2012,9,14]]},"references-count":2,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12006","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9,14]]}}}